RVL Pharmaceuticals PLC (RVLPQ)
0.00
USD |
OTCM |
May 16, 16:00
RVL Pharmaceuticals Cash from Financing (TTM): 38.28M for June 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | 38.28M |
| March 31, 2023 | 37.76M |
| December 31, 2022 | 41.78M |
| September 30, 2022 | 96.95M |
| June 30, 2022 | -131.35M |
| March 31, 2022 | -135.93M |
| December 31, 2021 | -135.33M |
| September 30, 2021 | -194.97M |
| June 30, 2021 | -32.00M |
| March 31, 2021 | -27.53M |
| Date | Value |
|---|---|
| December 31, 2020 | 3.682M |
| September 30, 2020 | 4.879M |
| June 30, 2020 | 26.05M |
| March 31, 2020 | 27.29M |
| December 31, 2019 | -4.691M |
| September 30, 2019 | 6.526M |
| June 30, 2019 | 6.127M |
| March 31, 2019 | 4.670M |
| December 31, 2018 | 3.604M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-194.97M
Minimum
Sep 2021
96.95M
Maximum
Sep 2022
-21.91M
Average
4.879M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | 1.313M |
| Palatin Technologies Inc | 14.71M |
| iBio Inc | 10.68M |
| Theriva Biologics Inc | 0.68M |
| Oragenics Inc | 0.2839M |